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Sirs, We appreciate the interest in our study from Professors Chen and Liaw and the 
opportunity to provide additional information.1 As we acknowledged in our paper, the wide 
confidence intervals for our risk estimates resulting from the relatively small number of 
case- and control-patients developing HCC were an important limitation to our study.2 Thus, 
it is possible that we failed to detect a real reduction in HCC risk because of insufficient 
statistical power. As requested, we recalculated the risk for developing HCC after excluding 
the 2 case-patients who received antiviral treatment before HBsAg seroclearance and the 32 
control-patients who had received antiviral treatment. After adjusting for age at cohort entry 
and initial anti-hepatitis B e antibody status, we did not detect a difference in HCC risk 
among case-compared with control-patients after excluding patients who had received 
antiviral treatment (adjusted hazard ratio: 0.7; 95% confidence interval: 0.2–2.7). The effect 
of age at HBsAg seroclearance on risk for HCC is complex and could be partly related to the 
specific HBV genotypes represented in a population. It has been demonstrated that the 
duration of hepatitis B e antigen persistence and the risk for HCC is substantially higher for 
persons with HBV genotype C compared with other genotypes.3,4 The majority of patients 
in the study indicating an increased risk for HCC among persons aged ≥50 years at the time 
of HBsAg seroclearance were infected with HBV genotype C.5,6 In contrast, the majority of 
patients in our study population were infected with HBV genotype D. Therefore, the risk for 
HCC associated with a later age of HBsAg seroclearance among Alaska Native persons 
compared with other geographic regions is unclear because of differences in the prevalence 
of HBV genotypes. Furthermore, the age at HBsAg seroclearance should not affect our 
interpretation of the relative risk for HCC between case- and control-patients because the 
majority of participants acquired HBV infection in early childhood and our analysis adjusted 
for case-patients’ HBsAg duration prior to seroclearance. We also speculated in our paper 
that ongoing low-level HBV DNA replication with continued integration into the host 
hepatocyte could have contributed to persistent HCC risk after HBsAg seroclearance. 
Further study is necessary to determine the relative importance of HBV viremia early in the 
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course of disease versus persistence of viremia after HBsAg clearance in the development of 
HCC.
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